S'abonner

A Brief Patient Self-administered Substance Use Screening Tool for Primary Care: Two-site Validation Study of the Substance Use Brief Screen (SUBS) - 17/06/15

Doi : 10.1016/j.amjmed.2015.02.007 
Jennifer McNeely, MD, MS a, b, , Shiela M. Strauss, PhD c, Richard Saitz, MD, MPH d, Charles M. Cleland, PhD c, Joseph J. Palamar, PhD, MPH a, John Rotrosen, MD e, Marc N. Gourevitch, MD, MPH a, b
a Department of Population Health, New York University (NYU) School of Medicine, New York 
b Department of Medicine, New York University (NYU) School of Medicine, New York 
c NYU College of Nursing, New York 
d Department of Community Health Sciences, School of Public Health and Clinical Research and Education Unit, Section of General Internal Medicine, Boston Medical Center, Boston, Mass 
e Department of Psychiatry, NYU School of Medicine, New York 

Requests for reprints should be addressed to Jennifer McNeely, MD, MS, NYU School of Medicine, 550 1st Ave., VZ30 6th Floor, New York, NY 10016.

Abstract

Background

Substance use screening is widely encouraged in health care settings, but the lack of a screening approach that fits easily into clinical workflows has restricted its broad implementation. The Substance Use Brief Screen (SUBS) was developed as a brief, self-administered instrument to identify unhealthy use of tobacco, alcohol, illicit drugs, and prescription drugs. We evaluated the validity and test-retest reliability of the SUBS in adult primary care patients.

Methods

Adults aged 18-65 years were enrolled from urban safety net primary care clinics to self-administer the SUBS using touch-screen tablet computers for a test-retest reliability study (n = 54) and a 2-site validation study (n = 586). In the test-retest reliability study, the SUBS was administered twice within a 2-week period. In the validation study, the SUBS was compared with reference standard measures, including self-reported measures and oral fluid drug tests. We measured test-retest reliability and diagnostic accuracy of the SUBS for detection of unhealthy use and substance use disorder for tobacco, alcohol, and drugs (illicit and prescription drug misuse).

Results

Test-retest reliability was good or excellent for each substance class. For detection of unhealthy use, the SUBS had sensitivity and specificity of 97.8% (95% confidence interval [CI], 93.7-99.5) and 95.7% (95% CI, 92.4-97.8), respectively, for tobacco; and 85.2% (95% CI, 79.3-89.9) and 77.0% (95% CI, 72.6-81.1) for alcohol. For unhealthy use of illicit or prescription drugs, sensitivity was 82.5% (95% CI, 75.7-88.0) and specificity 91.1% (95% CI, 87.9-93.6). With respect to identifying a substance use disorder, the SUBS had sensitivity and specificity of 100.0% (95% CI, 92.7-100.0) and 72.1% (95% CI, 67.1-76.8) for tobacco; 93.5% (95% CI, 85.5-97.9) and 64.6% (95% CI, 60.2-68.7) for alcohol; and 85.7% (95% CI, 77.2-92.0) and 82.0% (95% CI, 78.2-85.3) for drugs. Analyses of area under the receiver operating curve (AUC) indicated good discrimination (AUC 0.74-0.97) for all substance classes. Assistance in completing the SUBS was requested by 11% of participants.

Conclusions

The SUBS was feasible for self-administration and generated valid results in a diverse primary care patient population. The 4-item SUBS can be recommended for primary care settings that are seeking to implement substance use screening.

Le texte complet de cet article est disponible en PDF.

Keywords : Alcohol, Illicit drugs, Screening, Substance use, Tobacco, Validation


Plan


 Funding: National Institute on Drug Abuse K23 DA030395; National Institutes of Health/National Center for Advancing Translational Sciences UL1 TR000038; P30 DA011041. Additional funding was provided by subcontract from the MITRE Corporation (McLean, VA; who were contracted by the White House Office of the National Coordinator for Health Information Technology and Substance Abuse and Mental Health Services Administration).
 Conflict of Interest: None of the authors have a conflict of interest to report.
 Authorship: JM had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. JM was the principal investigator (PI) of the test-retest reliability study and the validation study at Site A, and led the analysis and writing. RS was site PI at Site B, and contributed to the study design. SMS and JR assisted with study design and advised on the analysis. CMC and JJP conducted the statistical analysis and assisted with data management. MNG played an instrumental role in conception and design of the study.


© 2015  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 128 - N° 7

P. 784.e9-784.e19 - juillet 2015 Retour au numéro
Article précédent Article précédent
  • Etiology of Pericarditis in a Prospective Cohort of 1162 Cases
  • Frédérique Gouriet, Pierre-Yves Levy, Jean-Paul Casalta, Christine Zandotti, Frédéric Collart, Hubert Lepidi, Jennifer Cautela, Jean Louis Bonnet, Franck Thuny, Gilbert Habib, Didier Raoult
| Article suivant Article suivant
  • Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Hypermetabolism of Vertebral Arteries Revealing Giant Cell Arteritis
  • Aurélie Daumas, Manon Scafi, Estelle Jean, Manambina Andrianasolo, Serge Cammilleri, Audrey Benyamine, Brigitte Granel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.